A study comparing two treatments (Letrozole and Misoprostol) to help manage early missed miscarriage safely in the first trimester

Letrozole Prior to Misoprostol versus Misoprostol for termination of First Trimester missed Miscarriage: [A Randomized Controlled Clinical Trial]

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202510834974517

Enrollment

Registered

2025-10-31

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Missed abortion

Interventions

Letrozole pre misoprostol

Misoprostol only

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: maternal age 20–37 years gestational age between 6 and 12 weeks based on last menstrual period and ultrasound singleton pregnancy hemoglobin =10.5 g/dl BMI 16–28 kg/m² hemodynamic stability

Exclusion criteria

Exclusion criteria: uterine anomalies (septate or bicornuate uterus) fibroids coagulopathy breastfeeding undiagnosed adnexal masses hypersensitivity to misoprostol or letrozole intrauterine device in situ heterotopic pregnancy chronic liver disease, heart disease, or bronchial asthma.

Design outcomes

Primary

Measure	Time frame
rate of complete abortion and time from initiation of treatment to complete expulsion.	—

Secondary

Measure	Time frame
adverse effects, severity of pain and bleeding, and need for surgical intervention	—

Countries

Egypt

Contacts

Public ContactAsmaa Elbahnasy

Demonastrator

Asmaaelbahnasy@gmail.com0201144003885

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026